AU2847199A - Crystalline form of paroxetine - Google Patents

Crystalline form of paroxetine Download PDF

Info

Publication number
AU2847199A
AU2847199A AU28471/99A AU2847199A AU2847199A AU 2847199 A AU2847199 A AU 2847199A AU 28471/99 A AU28471/99 A AU 28471/99A AU 2847199 A AU2847199 A AU 2847199A AU 2847199 A AU2847199 A AU 2847199A
Authority
AU
Australia
Prior art keywords
paroxetine
free base
crystalline
product
paroxetine free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28471/99A
Other languages
English (en)
Inventor
Andrew Simon Craig
Wilson Mcilwaine
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805581.7A external-priority patent/GB9805581D0/en
Priority claimed from GBGB9813054.5A external-priority patent/GB9813054D0/en
Priority claimed from GBGB9817115.0A external-priority patent/GB9817115D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2847199A publication Critical patent/AU2847199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU28471/99A 1998-03-16 1999-03-16 Crystalline form of paroxetine Abandoned AU2847199A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9805581 1998-03-16
GBGB9805581.7A GB9805581D0 (en) 1998-03-16 1998-03-16 Novel compounds
GBGB9813054.5A GB9813054D0 (en) 1998-06-17 1998-06-17 Novel compounds
GB9813054 1998-06-17
GB9817115 1998-08-06
GBGB9817115.0A GB9817115D0 (en) 1998-08-06 1998-08-06 Novel compounds
PCT/GB1999/000793 WO1999047519A1 (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Publications (1)

Publication Number Publication Date
AU2847199A true AU2847199A (en) 1999-10-11

Family

ID=27269245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28471/99A Abandoned AU2847199A (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Country Status (18)

Country Link
EP (1) EP1064282A1 (ru)
JP (1) JP2002506865A (ru)
KR (1) KR20010041947A (ru)
CN (1) CN1300286A (ru)
AP (1) AP2000001907A0 (ru)
AU (1) AU2847199A (ru)
BG (1) BG104839A (ru)
BR (1) BR9908825A (ru)
CA (1) CA2323896A1 (ru)
EA (1) EA200000946A1 (ru)
HU (1) HUP0101215A3 (ru)
ID (1) ID27596A (ru)
IL (1) IL138390A0 (ru)
NO (1) NO20004583L (ru)
PL (1) PL342931A1 (ru)
SK (1) SK13622000A3 (ru)
TR (1) TR200002675T2 (ru)
WO (1) WO1999047519A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie

Also Published As

Publication number Publication date
ID27596A (id) 2001-04-12
EA200000946A1 (ru) 2001-02-26
HUP0101215A2 (hu) 2002-04-29
HUP0101215A3 (en) 2002-05-28
BG104839A (en) 2001-09-28
KR20010041947A (ko) 2001-05-25
CA2323896A1 (en) 1999-09-23
IL138390A0 (en) 2001-10-31
SK13622000A3 (sk) 2001-03-12
TR200002675T2 (tr) 2000-12-21
BR9908825A (pt) 2000-11-21
PL342931A1 (en) 2001-07-16
WO1999047519A1 (en) 1999-09-23
JP2002506865A (ja) 2002-03-05
CN1300286A (zh) 2001-06-20
NO20004583L (no) 2000-09-15
NO20004583D0 (no) 2000-09-14
EP1064282A1 (en) 2001-01-03
AP2000001907A0 (en) 2000-09-30

Similar Documents

Publication Publication Date Title
EP0808314B1 (en) Forms of paroxetin hydrochloride
US5856493A (en) Process for making novel form of paroxeting hydrochloride anhydrate
EA025438B1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
GB2367003A (en) Paroxetine methansulphonate compositions
US20150266860A1 (en) Crystalline form of a drug
US20060189675A1 (en) Crystalline form of a drug
US20060063825A1 (en) Crystalline form of a drug
EP1137636A1 (en) Process for preparation of paroxetine maleate
WO2000035910A1 (en) Derivative of paroxetine
AU2847199A (en) Crystalline form of paroxetine
WO1994029303A1 (en) Heterocyclic chemistry
MXPA00009137A (es) Forma cristalina de paroxetina
WO2000032593A1 (en) Method of producing paroxetine hydrochloride
EP1135383B1 (en) Mixed paroxetine propan-2-ol solvates
AU1769899A (en) Process for the preparation of paroxetine hydrochloride
CZ20003343A3 (cs) Krystalická forma paroxetinu
US20020137938A1 (en) Novel process
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
WO2000032595A1 (en) Process for the production of paroxetine hydrochloride acetone solvate
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
EP1178962A1 (en) Process for the preparation of paroxetine acetate and analogues thereof
WO2000032592A1 (en) Process for the preparation of paroxetine hydrochloride
WO2000032596A1 (en) Amine salts of paroxetine
MXPA00006040A (en) Process for the preparation of paroxetine hydrochloride
WO2001025230A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted